At its meeting on December 12, the Supervisory Board of B. Braun SE appointed Dr. Jean-Claude Dubacher as a member of the Executive Board of B. Braun SE effective April 1, 2024. He will assume responsibility for the B. Braun Avitum division and at the same time become Chairman of the Executive Board of B. Braun Avitum AG. He will take over both functions from Anna Maria Braun, who is currently responsible for the division on an interim basis alongside her role as CEO of B. Braun SE.

Dr. Jean-Claude Dubacher joined the B. Braun Group on August 1, 2019. As Chairman of the Board and CEO of B. Braun of America, he successfully developed B. Braun’s US business. Dr. Dubacher has more than 20 years of experience in the healthcare industry, where he has worked in strategy, commercial, supply chain, and manufacturing. Before joining B. Braun, he was Head of Commercial Operations for Johnson & Johnson’s surgical ophthalmology division in Europe, the Middle East and Africa. Dr. Dubacher studied law at the University of Zurich and holds an MBA from Harvard Business School.

“I am delighted that we have once again been able to fill an Executive Board position from within our own ranks. Dr. Jean-Claude Dubacher brings additional internationality and comprehensive medical technology expertise to the Executive Board. The Board is therefore very well positioned to further B.􀯗Braun SE Corporate Communications Carl-Braun-Strasse 1 34212 Melsungen, Germany Contact: Christine Bossak presse@bbraun.com Phone: (05661) 711635 B. Braun is one of the world’s leading medical technology companies. With over 65,000 employees, B. Braun is a true partner developing smart solutions and setting standards to drive advancements in health care. In 2022, the B. Braun Group earned 8.5 billion euros in sales strengthen B. Braun as a leading medical technology company and to position it in the international markets,” says Prof. Dr. Thomas Rödder, Chairman of the Supervisory Board of B. Braun SE.

More information on www.bbraun.com